Targeting HIV-1 through molecular modeling and docking studies of CXCR4: Leads for therapeutic development

被引：19

作者：

Singh, Shailza ^{[1
]}

Malik, B. K.

Sharma, D. K.

机构：

[1] Indian Inst Technol, Ctr Energy Studies, New Delhi 110016, India

[2] CSIR, Inst Genom & Integrat Biol, New Delhi 110007, India

来源：

CHEMICAL BIOLOGY & DRUG DESIGN | 2007年 / 69卷 / 03期

关键词：

CXCR4; docking; flavonoids; human immunodeficiency virus; molecular modeling; AIDS-RELATED-COMPLEX; ENTRY INHIBITORS; ANTIRETROVIRAL THERAPY; CHEMOKINE RECEPTORS; AZIDOTHYMIDINE AZT; PROTEIN-STRUCTURE; CD4; RECEPTOR; DOUBLE-BLIND; MIP-1; ALPHA; VIRUS;

D O I：

10.1111/j.1747-0285.2007.00478.x

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The chemokine receptor CXCR4 is the receptor for several chemokines and major co-receptor for X4 human immunodeficiency virus type-1 strains entry into cell. A three-dimensional model of human CXCR4 was developed by homology modeling using the high-resolution bovine rhodopsin structure as template. Interactions between CXCR4 and flavonoids were investigated using in silico docking studies. The results underscore the potential of these compounds that they may become important new antiviral drugs to combat AIDS. It is worth mentioning also that apart from these existing flavonoids, there are many new compounds that may also be useful as topical agents to inactivate virus, or may act as adjuvants with other antiviral drugs.

引用

页码：191 / 203

页数：13

共 50 条

[1] Targeting Chemokine Receptor CXCR4 for Treatment of HIV-1 Infection, Tumor Progression, and Metastasis
Choi, Won-Tak
Yang, Yilei
Xu, Yan
An, Jing
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2014, 14 (13) : 1574 - 1589
[2] Molecular docking, QPLD, and ADME prediction studies on HIV-1 integrase leads
Tripathi, Sunil Kumar
Selvaraj, Chandrabose
Singh, Sanjeev Kumar
Reddy, Karnati Konda
MEDICINAL CHEMISTRY RESEARCH, 2012, 21 (12) : 4239 - 4251
[3] A Novel CXCR4 Targeting Protein SDF-1/54 as an HIV-1 Entry Inhibitor
Tan, Suiyi
Li, Wenjuan
Li, Zhaofeng
Li, Yujing
Luo, Jiangyan
Yu, Liangzhentian
Yang, Jie
Qiu, Mengjie
Cheng, Hongyan
Xu, Wei
Jiang, Shibo
Lu, Lu
Liu, Shuwen
Ma, Weifeng
VIRUSES-BASEL, 2019, 11 (09):
[4] The CXCL12/CXCR4 Axis as a Therapeutic Target in Cancer and HIV-1 Infection
Patrussi, L.
Baldari, C. T.
CURRENT MEDICINAL CHEMISTRY, 2011, 18 (04) : 497 - 512
[5] Molecular docking, QPLD, and ADME prediction studies on HIV-1 integrase leads
Sunil Kumar Tripathi
Chandrabose Selvaraj
Sanjeev Kumar Singh
Karnati Konda Reddy
Medicinal Chemistry Research, 2012, 21 : 4239 - 4251
[6] Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4
N Zhou
J Fang
M Mukhtar
E Acheampong
RJ Pomerantz
Gene Therapy, 2004, 11 : 1703 - 1712
[7] Nitrogen positional scanning in tetramines active against HIV-1 as potential CXCR4 inhibitors
Puig de la Bellacasa, Raimon
Gibert, Albert
Planesas, Jesus M.
Ros-Blanco, Laia
Batllori, Xavier
Badia, Roger
Clotet, Bonaventura
Este, Jose
Teixido, Jordi
Borrell, Jose I.
ORGANIC & BIOMOLECULAR CHEMISTRY, 2016, 14 (04) : 1455 - 1472
[8] CXCR4 Targeting Nanoplatform for Transcriptional Activation of Latent HIV-1 Infected T Cells
Vasukutty, Arathy
Pillarisetti, Shameer
Choi, Jonghoon
Kang, Shin Hyuk
Park, In-Kyu
ACS APPLIED BIO MATERIALS, 2023, 7 (08) : 4831 - 4842
[9] Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4
Zhou, N
Fang, J
Mukhtar, M
Acheampong, E
Pomerantz, RJ
GENE THERAPY, 2004, 11 (23) : 1703 - 1712
[10] NK Cells Acquire CCR5 and CXCR4 by Trogocytosis in People Living with HIV-1
Dang-Nghiem Vo
Leventoux, Nicolas
Campos-Mora, Mauricio
Gimenez, Sandrine
Corbeau, Pierre
Villalba, Martin
VACCINES, 2022, 10 (05)

← 1 2 3 4 5 →